Intended for healthcare professionals

Latest dermatology news

 

Nivolumab plus relatlimab hits primary endpoint in melanoma trial

Fixed dose combination of nivolumab and relatlimab improved progression free survival

06 Apr 2021

Larger surgical margins linked to survival in Merkel cell carcinoma

Local excision margins larger than 1.0 cm associated with improvements in overall survival

06 Apr 2021

Antibody drug candidate imsidolimab shows no benefit in palmoplantar pustulosis

Imsidolimab treatment did not significantly improve over placebo.

31 Mar 2021

Abrocitinib reduces signs and symptoms of atopic dermatitis

IGA response observed in 48.4% of patients treated with abrocitinib 200mg

31 Mar 2021

Guselkumab achieves long-term skin clearance in adult psoriatic arthritis patients

Late-stage data shows more than 50% of patients achieved complete skin clearance through two years of treatment

25 Mar 2021

Depression, anxiety linked to discordance in psoriasis severity assessments

Study finds patient overestimation of psoriasis severity is associated with mental health status

25 Mar 2021

Dermatology in practice was previously supported by Wyeth from 2008 to 2010, by Wyeth and Serono in 2007, by Wyeth and Shire from 2005 to 2006, by Medlock Medical in 2004 and by SSL International from 2001 to 2003.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the publisher, Editor or Editorial Board. Accordingly the publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Dermatology in practice is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2021 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 0262-5504 (Print) ISSN 2049-8446 (Online)